跳至主要内容
临床试验/NCT00318617
NCT00318617终止不适用

A Two Part Study to Separately Evaluate the Effect of 4-week Treatment With GW501516X Relative to Placebo on Cardiac Energetics in a Randomized, Single-blind, Repeat Dose, Parallel Group Design in Healthy Male Subjects

GlaxoSmithKline1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2005年12月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
终止
入组人数
30
试验地点
1
主要终点
Energy-related chemicals and heart contraction, determined by MRI measurement of the heart.

研究概览

简要总结

The purpose of this study is to determine the effect of a 4-week treatment period with GW501516X on how the heart obtains and uses energy. The energy of the heart will be measured by Magnetic Resonance Imaging (MRI). This study will also measure a number of other potential markers of drug activity, including levels of certain lipids (fats) and proteins in your blood. The data from this study may help researchers better understand the actions of this drug in the body and if this drug may be useful to treat patients with heart disease.

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Energy-related chemicals and heart contraction, determined by MRI measurement of the heart.

次要结局

  • Additional energy-related chemicals, determined by MRI measurement of the heart. Blood proteins. Safety of GW501516X.

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验